Evidence map›Paper›PMID 38619575›Full record

Observational studyClinical research in cardiology : official journal of the German Cardiac Society2025

Safety and feasibility of early discharge after transcatheter aortic valve implantation with ACURATE Neo-the POLESTAR trial.

Joris F Ooms, Kristoff Cornelis, Harindra C Wijeysundera, Bert Vandeloo, Jan Van Der Heyden, Jan Kovac, David Wood, Albert Chan, Joanna Wykrzykowska, Liesbeth Rosseel and 6 more

Erratum issuedOpen access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical research in cardiology : official journal of the German Cardiac Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Is next-day discharge after uncomplicated transcatheter aortic valve implantation the new standard of care?EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 4 countries.

Joris F OomsDepartment of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-7881-7609
Kristoff CornelisAZ Maria Middelares, Ghent, Belgium.
Harindra C WijeysunderaSunnybrook Health Sciences Centre, Toronto, ON, Canada.
Bert VandelooUniversity Hospital Brussels, Brussels, Belgium.
Jan Van Der HeydenSint Jan Hospital, Brugge, Belgium.
Jan KovacUniversity Hospitals Leicester NHS Trust, Leicester, UK.
David WoodCentre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Albert ChanRoyal Columbian Hospital, New Westminster, BC, Canada.
Joanna WykrzykowskaUniversity Medical Center Groningen, Groningen, The Netherlands.
Liesbeth RosseelASZ Aalst, Aalst, Belgium.
Michael CunningtonLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Frank van der KleyLeiden University Medical Center, Leiden, The Netherlands.
Benno RensingSint Antonius Hospital, Nieuwegein, The Netherlands.
Michiel VoskuilUniversity Medical Center Utrecht, Utrecht, The Netherlands.
David Hildick-SmithUniversity Hospitals Brighton and Sussex NHS Trust, Brighton, UK.
Nicolas M Van MieghemDepartment of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. n.vanmieghem@erasmusmc.nl.
Erasmus MC · NLAZ Maria Middelares · BEAZ Sint-Jan · BEFlanders Environment Agency · BELeeds Teaching Hospitals NHS Trust · GBLeiden University Medical Center · NLRoyal Columbian Hospital · CASt. Antonius Ziekenhuis · NLSunnybrook Health Science Centre · CAUniversity Hospitals of Leicester NHS Trust · GBUniversity Hospitals Sussex NHS Foundation Trust · GBUniversity Medical Center Groningen · NLUniversity Medical Center Utrecht · NLUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranscatheter aortic valve implantation (TAVI) serves a growing range of patients with severe aortic stenosis (AS). TAVI has evolved to a streamlined procedure minimizing length of hospital stay.

aimsTo evaluate the safety and efficacy of an early discharge (ED) strategy after TAVI.

methodsWe performed an international, multi-center, prospective observational single-arm study in AS patients undergoing TAVI with the ACURATE valve platform. Eligibility for ED was assessed prior to TAVI and based on prespecified selection criteria. Discharge ≤ 48 h was defined as ED. Primary Valve Academic Research Consortium (VARC)-3-defined 30-day safety and efficacy composite endpoints were landmarked at 48 h and compared between ED and non-ED groups.

resultsA total of 252 patients were included. The median age was 82 [25th-75th percentile, 78-85] years and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score was 2.2% [25th-75th percentile, 1.6-3.3]. ED and non-ED were achieved in 173 (69%) and 79 (31%) patients respectively. Monitoring for conduction disturbances was the principal reason for non-ED (33%). Overall, at 30 days, all-cause mortality was 1%, new permanent pacemaker rate was 4%, and valve- or procedure-related rehospitalization was 4%. There was no difference in the primary safety and efficacy endpoint between the ED and non-ED cohorts (OR 0.84 [25th-75th percentile, 0.31-2.26], p = 0.73, and OR 0.97 [25th-75th percentile, 0.46-2.06], p = 0.94). The need for rehospitalization was similarly low for ED and non-ED groups.

conclusionEarly discharge after TAVI with the ACURATE valve is safe and feasible in selected patients. Rhythm monitoring and extended clinical observation protracted hospital stay.

Indexed as

Aortic ValveAortic Valve StenosisHeart Valve ProsthesisPatient DischargeTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFeasibility StudiesFemaleFollow-Up StudiesHumansLength of StayMalePostoperative ComplicationsProspective StudiesProsthesis DesignEarly dischargeSelf-expanding valveTAVI

Identifiers

PMID38619575
PMCPMC11913897
OpenAlexW4394815637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.